PHARLEVO

(Levofloxacin)

Pharlevo 250mg 500mg Tablets

COMPOSITION:

Each Film Coated tablet contains,

Levofloxacin (as hemihydrate) USP 250mg, 500mg and 750mg

INDICATIONS:

• Pneumonia
• Sinus infection
• Worsening of chronic bronchitis
• Skin infections
• Chronic prostate infection.
• Urinary tract infections
• Pyelonephritis
• Inhalational anthrax
• Plague

MODE OF ACTION:

• Inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases),

Gram-Positive Bacteria

• Enterococcus faecalis
• Staphylococcus aureus (methicillin-susceptible isolates)
• Staphylococcus epidermidis (methicillin-susceptible Isolates)
• Staphylococcus saprophyticus
• Streptococcus pneumoniae (including multi-drug resistant isolates [MDRSP]1)
• Streptococcus pyogenes

Gram-Negative Bacteria

• Enterobacter cloacae
• Escherichia coli
• Hemophilus influenza
• Hemophilus parainfluenza
• Klebsiella pneumoniae
• Legionella pneumophila
• Moraxella catarrhalis
• Proteus mirabilis
• Pseudomonas aeruginosa
• Serratia marcescens

DOSAGE RECOMMENDATIONS:

• For treatment of mild to moderate uncomplicated UTI.

Oral dosage Adults

250 mg PO every 24 hours for 3 days. Due to the risk for serious and potentially permanent side effects associated with fluoroquinolone antibiotics, levofloxacin should only be used in cases where alternative treatment options cannot be used.

• For the treatment of acute bacterial exacerbation of chronic bronchitis.

Oral dosage Adults

500 mg PO every 24 hours for 7 days. Due to the risk for serious and potentially permanent side effects associated with fluoroquinolone antibiotics, levofloxacin should only be used in cases where alternative treatment options cannot be used.

• For the treatment of uncomplicated typhoid fever, caused by Salmonella typhi.

Oral dosage Adults

Doses of 500 mg PO once daily for 7 days and 750 mg PO once daily for 5 days have been used successfully in open-label studies